Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 September 2020Website:
http://www.athira.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 5 min agoDividend
Analysts recommendations
Institutional Ownership
ATHA Latest News
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced the appointment of Erinn Broshko as a non-executive director and Rhéal Assié as chief financial officer, starting November 6. The company said Broshko, a seasoned executive and lawyer, brings more than 25 years of experience in law, business, and leadership, including roles as CEO and executive chairman in biotech and energy services.
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that it has entered into option agreement with Terra Uranium Ltd (ASX:T92) which allow the two companies to earn significant interest in each other's uranium exploration projects. ATHA has granted Terra Uranium an option to acquire up to 70% interest in its Spire and Horizon properties, together the Spire Horizon projects.
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure that extends from the Athabasca Basin to the Angikuni Basin.
Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced it has completed its 2024 Exploration Program at its Angilak uranium project in Nunavut, which hosts the Lac 50 uranium Deposit. The “highly successful” program was carried out from early June to late August and involved 25 diamond drill holes totalling about 10,051 meters.
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has provided investors with an update on its 2024 exploration programs at its uranium projects. At its Gemini project in the Athabasca Basin, Saskatchewan, the company in late August kicked off a Phase 3 diamond drill program to expand the footprint of mineralization, targeting the down-dip extents of the Gemini Mineralized Zone (GMZ).
VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSXV: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Terra Uranium Ltd. (ASX: T92) (“T92”), whereby the parties will work to negotiate a definitive option and joint venture agreement for T92 to earn an option to acquire a 70% interest in ATHA's Spire and Horizon properties (together, the “Spire Horizon Projects”) and a definitive option and joint venture agreement for ATHA to earn an option to acquire up to a 60% interest in T92's Pasfield Lake property (the “Pasfield Project”).
Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2024, and provided recent pipeline and business updates.
- 1(current)
What type of business is Athira Pharma?
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
What sector is Athira Pharma in?
Athira Pharma is in the Healthcare sector
What industry is Athira Pharma in?
Athira Pharma is in the Biotechnology industry
What country is Athira Pharma from?
Athira Pharma is headquartered in United States
When did Athira Pharma go public?
Athira Pharma initial public offering (IPO) was on 18 September 2020
What is Athira Pharma website?
https://www.athira.com
Is Athira Pharma in the S&P 500?
No, Athira Pharma is not included in the S&P 500 index
Is Athira Pharma in the NASDAQ 100?
No, Athira Pharma is not included in the NASDAQ 100 index
Is Athira Pharma in the Dow Jones?
No, Athira Pharma is not included in the Dow Jones index
When was Athira Pharma the previous earnings report?
No data
When does Athira Pharma earnings report?
The next expected earnings date for Athira Pharma is 21 February 2025